<DOC>
	<DOCNO>NCT00126646</DOCNO>
	<brief_summary>RATIONALE : BL22 immunotoxin find tumor cell kill without harm normal cell . PURPOSE : This phase I trial study side effect best dose BL22 immunotoxin treat patient refractory B-cell chronic lymphocytic leukemia , prolymphocytic leukemia , non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>BL22 Immunotoxin Treating Patients With Refractory Chronic Lymphocytic Leukemia , Prolymphocytic Leukemia , Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recombinant BL22 immunotoxin patient CD22-positive refractory B-cell chronic lymphocytic leukemia , prolymphocytic leukemia , indolent non-Hodgkin 's lymphoma . - Determine safety efficacy drug patient . - Determine pharmacokinetics drug patient . - Determine immunogenicity drug patient . - Determine effect drug various component circulate cellular immune system patient . OUTLINE : This nonrandomized , dose-escalation study . Patients stratify accord disease type ( chronic lymphocytic leukemia v non-Hodgkin 's lymphoma ) . Patients receive recombinant BL22 immunotoxin IV 30 minute day 1 , 3 , 5 . Treatment repeat ≥ every 27 day 6 course absence neutralize antibody BL22 PE38 , disease progression , unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . Patients relapse CR last ≥ 6 month may receive additional course . Cohorts 3-6 patient per stratum receive escalate dos recombinant BL22 immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 24 patient ( 12 per stratum ) accrue study within 1-2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell leukemia lymphoma 1 follow type : Chronic lymphocytic leukemia Failed standard chemotherapy Prolymphocytic leukemia Failed standard chemotherapy Indolent nonHodgkin 's lymphoma , include mantle cell lymphoma Stage III IV disease Failed ≥ 1 prior doxorubicin fludarabinecontaining standard therapy CD22positive disease , evidence 1 follow : More 15 % malignant cell react antiCD22 immunohistochemistry More 30 % malignant cell CD22positive fluorescenceactivated cell sort analysis More 400 CD22 site per malignant cell ( average ) radiolabeled antiCD22 binding Treatment medically indicate , evidence following : Progressive diseaserelated symptom Progressive cytopenia due marrow involvement Progressive painful splenomegaly adenopathy Rapidly increase lymphocytosis Autoimmune hemolytic anemia thrombocytopenia Increased frequency infection No neutralize antitoxin antimouse immunoglobulin G ( IgG ) antibodies BL22 PE38 No serum neutralization &gt; 75 % activity 1 μg/mL BL22 No CNS disease require treatment No hairy cell leukemia PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy More 6 month Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3* Platelet count &gt; 40,000/mm^3 NOTE : *Patients leukemia eligible regardless absolute neutrophil count ; Grade IIIIV pancytopenia growth factor dependence allow due disease Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) ALT AST &lt; 2.5 time ULN Renal Creatinine ≤ 1.5 mg/dL Pulmonary FEV1 ≥ 60 % predict DLCO ≥ 55 % predict Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Prior bone marrow transplantation allow More 3 week since prior biologic therapy , include interferon , denileukin diftitox , LMB2 immunotoxin More 3 month since prior monoclonal antibody therapy ( e.g. , rituximab ) Chemotherapy See Disease Characteristics More 3 week since prior cytotoxic chemotherapy Endocrine therapy More 1 week since prior steriods Less 5 dos nontreatment reason ( e.g. , allergy prophylaxis ) No evidence disease response Radiotherapy More 3 week since prior wholebody electron beam radiotherapy Radiotherapy within past 3 week allow provided volume bone marrow treat &lt; 10 % AND patient measurable disease locate outside radiation port Surgery Not specify Other More 3 week since prior retinoids More 3 week since prior systemic therapy malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
</DOC>